Patents by Inventor Hassan El Abdellaoui

Hassan El Abdellaoui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereof
    Patent number: 9198901
    Abstract: The invention provides tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The invention further provides solid compositions comprising tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The invention further provides uses of tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist, e.g., for treating type 1 diabetes, type 2 diabetes, or obesity.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: December 1, 2015
    Assignee: vTv Therapeutics LLC
    Inventors: Danilo Almariego, Dharma Rao Polisetti, Eric Benjamin, Hassan El Abdellaoui, Soumya P. Sahoo
  • Tris(hydroxymethyl)Aminomethane Salts of a Small-Molecule GLP1R Agonist and Pharmaceutical Compositions and Uses Thereof
    Publication number: 20150005339
    Abstract: The invention provides tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The invention further provides solid compositions comprising tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist. The invention further provides uses of tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist, e.g., for treating type 1 diabetes, type 2 diabetes, or obesity.
    Type: Application
    Filed: September 18, 2014
    Publication date: January 1, 2015
    Inventors: Danilo Almariego, Dharma Rao Polisetti, Eric Benjamin, Hassan El Abdellaoui, Soumya P. Sahoo
  • Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
    Patent number: 8350039
    Abstract: The present invention is directed to substituted isoquinoline derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.
    Type: Grant
    Filed: August 22, 2011
    Date of Patent: January 8, 2013
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Hassan El Abdellaoui, Mohan Rao, Pingzhen Wang, Robert Carl Andrews, Rongyuan Xie, Tan Ren
  • SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
    Publication number: 20120101093
    Abstract: The present invention is directed to substituted imidazo[1,2-a]pyridine derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.
    Type: Application
    Filed: August 22, 2011
    Publication date: April 26, 2012
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: Adnan M. M. Mjalli, Anitha Hari, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Hassan El Abdellaoui, Mohan Rao, Robert Carl Andrews, Rongyuan Xie, Tan Ren
  • SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
    Publication number: 20120101125
    Abstract: The present invention is directed to substituted isoquinoline derivatives, pharmaceutically acceptable salts thereof, and tautomers of such compounds or salts, that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which BACE is involved.
    Type: Application
    Filed: August 22, 2011
    Publication date: April 26, 2012
    Applicant: HIGH POINT PHARMACEUTICALS, LLC
    Inventors: Adnan M. M. Mjalli, Bapu Gaddam, Devi Reddy Gohimukkula, Dharma Rao Polisetti, Hassan El Abdellaoui, Mohan Rao, Pingzhen Wang, Robert Carl Andrews, Rongyuan Xie, Tan Ren
  • Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
    Patent number: 8101799
    Abstract: This invention concerns N—(2-arylamino) aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: January 24, 2012
    Assignee: Ardea Biosciences
    Inventors: Andreas Maderna, Jean-Michel Vernier, Dinesh Barawkar, Varaprasad Chamakura, Hassan El Abdellaoui, Zhi Hong
  • Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
    Patent number: 7759518
    Abstract: This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: July 20, 2010
    Assignee: Ardea Biosciences
    Inventors: Andreas Maderna, Jean-Michel Vernier, Dinesh Barawkar, Varaprasad Chamakura, Hassan el Abdellaoui, Zhi Hong
  • Phenylamino isothiazole carboxamidines as MEK inhibitors
    Patent number: 7652047
    Abstract: The invention concerns compounds which inhibit MEK and which have activity as anti-neoplastic agents. These compounds include N-substituted-3-hydroxy-5-arylamino-isothiazole-4-carboxamidines. Also included are the tautomeric isothiazol-3(2H)-ones.
    Type: Grant
    Filed: July 11, 2008
    Date of Patent: January 26, 2010
    Assignee: Ardea Biosciences, Inc.
    Inventors: Hassan El Abdellaoui, Robert Tam, Huanming Chen, Varaprasad Chamakura, Dinesh Barawkar, Andreas Maderna, Zhi Hong, Stanley Lang
  • DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK
    Publication number: 20090082457
    Abstract: This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.
    Type: Application
    Filed: November 25, 2008
    Publication date: March 26, 2009
    Applicant: Andrea Biosciences, Inc.
    Inventors: Andreas MADERNA, Jean-Michel VERNIER, Dinesh BARAWKAR, Varaprasad CHAMAKURA, Hassan EL ABDELLAOUI, Zhi HONG
  • DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK
    Publication number: 20080058340
    Abstract: This invention concerns N-(2-arylamino) aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.
    Type: Application
    Filed: July 30, 2007
    Publication date: March 6, 2008
    Applicant: ARDEA BIOSCIENCES, INC.
    Inventors: Andreas Maderna, Jean-Michel Vernier, Dinesh Barawkar, Varaprasad Chamakura, Hassan El Abdellaoui, Zhi Hong